

4 May 2023

Inspiration Healthcare Group plc
("Inspiration Healthcare", the "Company" or the "Group")

Investor Day

Inspiration Healthcare Group plc (AIM: IHC), the global medical technology company, announces that it will hold an Open Day for investors at the Company's headquarters in Croydon, South London on Wednesday, 7 June 2023 from 10am to 1pm. The day is open to all existing and potential investors, and to anyone who wishes to meet the Company and hear the story.

Management will also present an update on trading for the year ended 31 January 2023 following the release of the Company's Preliminary Results on 3 May 2023.

The day will provide an opportunity for investors to meet the Senior Management team, take a tour of the facility and familiarise themselves with the Company's products. This will be followed by a light lunch.

If you wish to attend, please register through Walbrook PR to reserve a space, which are limited. This can be done either by emailing inspirationhealthcare@walbrookpr.com or calling Walbrook PR on the number below.

For further information:

Inspiration Healthcare Group plc

Tel: +44 (0)330 175 0000

Neil Campbell, Chief Executive Officer
Paul Bergin, Interim Chief Financial Officer

Cenkos Securities plc (Nominated Adviser & Broker)
Stephen Keys, Katy Birkin, Dan Hodgkinson

Tel: +44 (0)207 397 8900

Walbrook PR Ltd (Media and Investor Relations)

Tel: +44 (0)20 7933 8780 or
inspirationhealthcare@walbrookpr.com

Anna Dunphy
Stephanie Cuthbert

Mob: +44 (0) 7876 741 001
Mob: +44 (0) 7796 794 663

About Inspiration Healthcare

Inspiration Healthcare (AIM: IHC) is a global provider of medical technology for use in neonatal intensive care & operating theatres. The Company provides high quality innovative products to patients around the world which help to improve patient outcomes and it actively invests in innovative product opportunities and disruptive technologies.

The Company has key own brand products that can be used within the first days of life to help premature and sick babies; helping resuscitation and stabilisation in the first moments of life through to preventing brain damage and both invasive and non-invasive respiratory support in terms of capital equipment and disposable medical devices. Additionally, the Company has its own range of products for maintaining normothermia pre, during and post-surgery.

Since September 2019, the Company has acquired Vio Holdings a designer, manufacturer and supplier of single use respiratory products and sterile medical consumables and S.L.E., a leading designer, manufacturer and global provider of neonatal ventilation products. The Group generates approximately 58% of its revenues from export markets and more than half of its revenues come from its own-branded products.

With product availability actively promoted to over 80 countries through a distribution network, Inspiration Healthcare's success has been built on continuous innovation, excellent customer service and an inherent commitment to improving patient outcomes, working in close collaboration with key opinion leaders across the globe.

In the UK and Ireland, the Group has direct sales teams selling Group Branded and complementary products from third parties, with an additional range of home healthcare products. This is supported by Technical Support for planned preventative maintenance and emergency assistance.

The Group operates from various sites in the UK for R&D, Marketing and operations with manufacturing based in Croydon (south London) and Hailsham (East Sussex). The Group's Head Office is located in Crawley, a short distance from London's Gatwick Airport.

Further information on Inspiration Healthcare can be found at www.inspirationhealthcaregroup.com

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRAAJMITMTBMAJ